Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series

• Main Authors: He X (Author), Yang D (Author), Lai L (Author), Lang J (Author), Wei K (Author), Xiao M (Author)
• Format: Book
• Published: Dove Medical Press, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1178-7015
• Keywords: upadacitinib; alopecia areata; jak inhibitors; jak-stat; Dermatology; RL1-803
• Source: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 565-571 (2024)

Xin He,1,2 Dongyue Yang,1,2 Lingyao Lai,1,2 Jing Lang,1,2 Kebo Wei,1,2 Min Xiao1 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China; 2School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of ChinaCorrespondence: Min Xiao, Email [e-mail]: Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients.Keywords: upadacitinib, alopecia areata, JAK inhibitors, JAK-STAT